Finance

Lists
Why is 1OT up 5,88%?
Dive Deeper
1OT:FRA
Ovid Therapeutics Inc
2,16 €
+5,88%
(+0,12) 1D
12-окт., 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 1OT...
Open
2,16 €
High
2,16 €
Low
2,16 €
Mkt. cap
470,67 млн
Avg. vol.
2,00
Volume
0,00
52-wk high
2,52 €
52-wk low
0,97 €
No. of employees
23
Open
2,16 €
High
2,16 €
Low
2,16 €
Mkt. cap
470,67 млн
Avg. vol.
2,00
Volume
0,00
52-wk high
2,52 €
52-wk low
0,97 €
No. of employees
23
News stories
From web sources and news partners
About Ovid Therapeutics Inc
CEO-
Employees23
Founded2014
Headquarters-
Sector-
Websiteovidrx.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
132,00 миң
718,00 миң
-
733,00 миң
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
5,87 млн
6,59 млн
11,18 млн
9,96 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,78 млн
6,42 млн
6,66 млн
6,17 млн
Operating expense
12,66 млн
13,01 млн
17,85 млн
16,13 млн
Total operating expenses
12,66 млн
13,01 млн
17,85 млн
16,13 млн
Operating income
-12,52 млн
-12,29 млн
-17,85 млн
-15,40 млн
Other non operating income
62,00 миң
57,00 миң
121,00 миң
-869,00 миң
EBT including unusual items
-12,16 млн
9,66 млн
-16,99 млн
-15,01 млн
EBT excluding unusual items
-12,16 млн
-11,39 млн
-16,99 млн
-14,71 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12,16 млн
9,66 млн
-16,99 млн
-15,01 млн
Net profit margin
-9 210,61%
1 345,82%
-
-2 047,61%
Earnings per share
-0,17
0,06
-0,12
-0,08
Interest and investment income
303,00 миң
847,00 миң
737,00 миң
1,56 млн
Interest expense
-
-
-
-
Net interest expenses
303,00 миң
847,00 миң
737,00 миң
1,56 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-12,51 млн
-12,28 млн
-17,81 млн
-15,38 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору